Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boditech Med and SphingoTec Partner on Renal Damage Indicator

Boditech Med and SphingoTec Partner on Renal Damage Indicator

11th September 2023

A medical diagnostic test to evaluate kidney health and severe renal damage has been developed by Boditech Med and SphingoTec as part of a product collaboration.

The partnership builds upon a licence agreement made public in November 2022. Within this, Gangwon-do, South Korea-based Boditech is creating point-of-care assays including Hennigsdorf, a kidney performance biomarker (penKid) from SphingoTec.

Assays covered by the licencing agreement are made to work with Boditech’s AFIAS equipment.

The companies claimed that a blood-based penKid diagnostic offers a quicker and more precise assessment of kidney function than others on the market.

Growing biomarker levels may additionally be utilised to show acute renal damage faster than different diagnostic techniques.

Levels of the marker are unaffected other medical conditions like diabetes and hypertension, and research shows that penKid is effective in assessing kidney function in both adults and children.

The collaboration will offer substantial backing for the commercial launch of the penKid-based test, develop the identification process for acute kidney damage, and enhance the care of seriously sick patients, according to SphingoTec CEO Jörg Menten.

Economic parameters and other details of the partnership weren’t made public.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.